Gilead Sciences Inc.

United States of America Country flag United States of America
Sector: Biotechnology
Ticker: GILD
Factsheet Factsheet

Market multiple valuation of Gilead Sciences Inc. ( GILD | USA)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of Gilead Sciences Inc. is higher than the median of its peer group: around 12.00. The company valuation of Gilead Sciences Inc. according to these metrics is above the market valuation of its peer group.
The P/Earnings NTM ratio of Gilead Sciences Inc. is significantly lower than the average of its sector (Biotechnology): -3.22. The company valuation of Gilead Sciences Inc. according to these metrics is way below the market valuation of its sector.
The P/Earnings NTM ratio of Gilead Sciences Inc. is significantly higher than its historical 5-year average: 10.2. The (current) company valuation of Gilead Sciences Inc. is therefore way above its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2022P/E NTM
Gilead Sciences Inc.Free trialFree trialFree trial
International PeersFree trialFree trialFree trial
Biotechnology-4.80-3.25-3.22
NASDAQ 10034.8622.8322.69
United States of America-0.7911.5011.65
More...
Beta (Ref: NASDAQ 100)
Levered betaUnlevered beta
1-Year0.200.20
2-Year0.170.17
3-Year0.260.26
More...
Stock Perf excl. Dividends (in USD)
GILDNASDAQ 100Rel. Perf.
Year-to-Date-6.6%-9.0%2.4%
1-Week-5.7%-4.2%-1.5%
1-Month-6.4%-5.0%-1.4%
1-Year-0.3%11.7%-11.9%
3-Year-2.0%118.8%-120.8%
5-Year-4.5%193.2%-197.7%
More...
International Peers - Gilead Sciences Inc.
Company NameCtryMarket
Cap.
last (mUSD)
Gilead Sciences Inc.USA85 060
International Peers Median0.09
United Therapeutics Cor...USA9 006
Bristol-Myers Squibb Co...USA143 345
Pfizer Inc.USA303 375
GlaxoSmithKline plcGBR111 982
Merck & Co., Inc.USA203 970
GPRV Analysis
Gilead Sciences Inc.
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Gilead Sciences Inc.
  • NASDAQ 100
More...

Did you know ?

Multiples charts provide an effective way to quickly analyze a company's valuation over a period of time, and compare it against the valuation of another company, a personal list, or a market index.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).